Inhibitor Therapeutics (INTI) Return on Capital Employed Growth (1y) (2014 - 2026)
Inhibitor Therapeutics (INTI) Return on Capital Employed Growth (1y) (2014 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 45.00 |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -48.00 |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -785.00 |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 1,629.00 |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 3,193.00 |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -28.00 |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 399.00 |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -310.00 |
| 10 | Inhibitor Therapeutics | 15.64 Mn | 15.64 Mn | - | -30,156.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -14,577.00 |
| Dec 31, 2025 | -9,840.00 |
| Sep 30, 2025 | -5,379.00 |
| Jun 30, 2025 | -4,464.00 |
| Mar 31, 2025 | -2,786.00 |
| Dec 31, 2024 | -2,866.00 |
| Sep 30, 2024 | -2,465.00 |
| Jun 30, 2024 | -2,770.00 |
| Mar 31, 2024 | -3,267.00 |
| Dec 31, 2023 | -2,721.00 |
| Sep 30, 2023 | -5,164.00 |
| Jun 30, 2023 | -4,714.00 |
| Mar 31, 2023 | -4,315.00 |
| Dec 31, 2022 | -6,620.00 |
| Sep 30, 2022 | -4,860.00 |
| Jun 30, 2022 | -11,173.00 |
| Mar 31, 2022 | -25,000.00 |
| Dec 31, 2021 | -29,033.00 |
| Sep 30, 2021 | -47,591.00 |
| Jun 30, 2021 | -116,533.00 |